Izabela M.
- Country
- Poland
- Department
- Klinika Endokrynologii i Chorob Metabolicznych
Research Overview
- Evaluation of Romosozumab Versus Bisphosphonates in Pediatric Osteogenesis Imperfecta: A Phase 3, Open-Label, Multicenter, Randomized Study
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of ALXN1850 in Adolescents and Adults with Hypophosphatasia Naïve to Asfotase Alfa Treatment
- Efficacy and Safety Evaluation of ALXN1850 in Pediatric Patients with Hypophosphatasia: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 11 of 49 partner sites.
Specializations
Rare Metabolic Disorders
This investigator specializes in the study and treatment of hypophosphatasia (HPP), a rare inherited metabolic disorder affecting bone development and mineralization.
- Pediatric HPP Management
- Adolescent and Adult HPP Treatment
- Bone Mineralization Disorders
The investigator's work encompasses comprehensive research into therapeutic approaches for patients across different age groups affected by HPP.
Clinical Innovation
The investigator focuses on evaluating novel therapeutic interventions for metabolic bone disorders, with particular emphasis on treatment-naïve patients.
- Innovative Treatment Modalities
- Radiographic Outcome Assessment
- Functional Performance Evaluation
Their research aims to advance understanding of treatment efficacy in previously untreated HPP patients.
Patient Care Focus
The investigator's expertise extends to assessing therapeutic outcomes across diverse patient populations.
- Age-Specific Treatment Approaches
- Clinical Assessment Methods
- Patient Function Improvement
Their work emphasizes comprehensive evaluation of treatment effectiveness in improving patient quality of life.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.